The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study Group
Abstract
Purpose: Somatostatin analogs and interferon alfa control hormone-active/functional neuroendocrine gastroenteropancreatic tumors. In addition to hormonal control, variable degrees of antiproliferative effects for both agents have been reported. Until now, however, no prospective, randomized studies in therapy-naive patients have compared somatostatin analogs or interferon alfa alone with a combination of the two. Methods: Eighty therapy-naive patients with histologically verified neuroendocrine tumor disease (primary localization: foregut, n = 36; midgut, n = 30; hindgut, n = 3; unknown, n = 11; functional, n = 29; nonfunctional, n = 51) were randomly treated either with lanreotide (1 mg three times a day administered subcutaneously [SC]) or interferon alfa (5 × 10 6 U three times a week SC) or both. All patients had disease progression in the 3 months before study entry, verified with imaging procedures. Results: Twenty-five patients were treated with lanreotide, 27 patients were treated with interferon alfa, and 28 patients were treated with the combination. Partial tumor remission was seen in four patients (one patient who received lanreotide, one patient who received interferon alfa, and two patients who received the combination). During the 12 months of therapy, stable disease was observed in 19 patients (seven patients who received lanreotide, seven patients who received interferon alfa, and five patients who received the combination), whereas tumor progression occurred in 14 of 25 patients (lanreotide), 15 of 27 patients (interferon alfa), and 14 of 28 patients (combination). Side effects leading to an interruption of therapy were more frequent in the combination group than in the monotherapy arms. Conclusion: This prospective, randomized, multicenter study shows for the first time that somatostatin analogs, interferon alfa, or the combination of the two had comparable antiproliferative effects in the treatment of metastatic neuroendocrine gastroenteropancreatic tumors. Response rates were lower compared with those published in previous, nonrandomized studies. The antiproliferative effect of the tested substances was similar for functional and nonfunctional neuroendocrine tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple imputation in health‐are databases: An overview and some applications
Rubin, D. B., & Schenker, N. (1991) · Statistics in Medicine · doi:10.1002/sim.4780100410 · Cited by 1,550
Lamberts, S. W. J., van der Lely, A.-J., de Herder, W. W., & Hofland, L. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340408 · Cited by 1,001
Moertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., & Klaassen, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260804 · Cited by 976
Treatment of the Malignant Carcinoid Syndrome
Kvols, L. K., Moertel, C. G., O'Connell, M. J., Schutt, A. J., Rubin, J., & Hahn, R. G. (1986) · New England Journal of Medicine · doi:10.1056/nejm198609113151102 · Cited by 849
Moertel, C. G., Kvols, L. K., O'Connell, M. J., & Rubin, J. (1991) · Cancer · doi:10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i · Cited by 840
Arnold, R., Trautmann, M. E., Creutzfeldt, W., Benning, R., Benning, M., Neuhaus, C., Jürgensen, R., Stein, K., Schäfer, H., Bruns, C., et al. (1996) · Gut · doi:10.1136/gut.38.3.430 · Cited by 342
Öberg, K., Funa, K., & Alm, G. (1983) · New England Journal of Medicine · doi:10.1056/nejm198307213090301 · Cited by 275
Kubota, A., Yamada, Y., Kagimoto, S., Shimatsu, A., Imamura, M., Tsuda, K., Imura, H., Seino, S., & Seino, Y. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117090 · Cited by 269
Saltz, L., Trochanowski, B., Buckley, M., Heffernan, B., Niedzwiecki, D., Tao, Y., & Kelsen, D. (1993) · Cancer · doi:10.1002/1097-0142(19930701)72:1<244::aid-cncr2820720143>3.0.co;2-q · Cited by 260
Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer.
Buscail, L., Saint‐Laurent, N., Chastre, E., Vaillant, J., Gespach, C. P., Capellá, G., Kalthoff, H., Lluı́s, F., Vaysse, N., & Susini, C. (1996) · PubMed · Cited by 201
The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
Ducreux, M. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02003-7 · Cited by 196
Frank, M. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00146-x · Cited by 191
Eriksson, B., Renstrup, J., Imam, H., & Öberg, K. (1997) · Annals of Oncology · doi:10.1023/a:1008205415035 · Cited by 190
Revised Classification of Neuroendocrine Tumors of the Lung, Pancreas and Gut
Capella, C., Heitz, P. U., Höfler, H., Solcia, E., & Klöppel, G. (1994) · Digestion · doi:10.1159/000201197 · Cited by 186
Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumours
Janson, E. T., Ahlström, H. K., Andersson, T., & Öberg, K. E. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90060-f · Cited by 130
Faiss, S., Räth, U., Mansmann, U., Caird, D. M., Clemens, N., Riecken, E. O., & Wiedenmann, B. (1999) · Digestion · doi:10.1159/000007693 · Cited by 116
Self-citationSomatostatin Analogue Phase I Trials in Neuroendocrine Neoplasms
Anthony, L. B., Johnson, D. H., Hande, K. R., Shaff, M. I., Winn, S., Krozely, M. G., & Oates, J. (1993) · Acta Oncologica · doi:10.3109/02841869309083915 · Cited by 111
Weckbecker, G., Liu, R., Tolcsvai, L., & Bruns, C. (1992) · PubMed · Cited by 88
Detjen, K. M., Welzel, M., Farwig, K., Brembeck, F. H., Kaiser, A., Riecken, E.-O., Wiedenmann, B., & Rosewicz, S. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70143-0 · Cited by 71
Self-citationMolecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system
Wiedenmann, B., John, M., Ahnert‐Hilger, G., & Riecken, E. (1998) · Journal of Molecular Medicine · doi:10.1007/s001090050261 · Cited by 66
Self-citationDramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide
Joensuu, H., Kätkä, K., & Kujari, H. P. (1992) · European Journal of Endocrinology · doi:10.1530/acta.0.1260184 · Cited by 37
Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995)
Weckbecker, G., Tolcsvai, L., Liu, R., & Bruns, C. (1992) · Metabolism · doi:10.1016/0026-0495(92)90041-8 · Cited by 28
Progress against Rare and Not-So-Rare Cancers
Chabner, B. A., & Friedman, M. A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260811 · Cited by 21
Cited by
Rinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Self-citationGastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Pavel, M., Baudin, E., Couvelard, A., Krenning, E., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 873
Self-citation
Metadata
- Authors
- Faiss, S., Pape, U.-F., Böhmig, M., Dörffel, Y., Mansmann, U., Golder, W., Riecken, E. O., & Wiedenmann, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-07-15
- Volume
- 21
- Issue
- 14
- Pages
- 2689-2696
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2100283328
- Cited by
- 501
- References
- 23
- FWCI
- 17.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.